Literature DB >> 17920626

An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.

Emily J Platt1, James P Durnin, Ujwal Shinde, David Kabat.   

Abstract

Binding of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120 to the CCR5 co-receptor reduces constraints on the metastable transmembrane subunit gp41, thereby enabling gp41 refolding, fusion of viral and cellular membranes, and infection. We previously isolated adapted HIV-1(JRCSF) variants that more efficiently use mutant CCR5s, including CCR5(Delta18) lacking the important tyrosine sulfate-containing amino terminus. Effects of mutant CCR5 concentrations on HIV-1 infectivities were highly cooperative, implying that several may be required. However, because wild-type CCR5 efficiently mediates infections at trace concentrations that were difficult to measure accurately, analyses of its cooperativity were not feasible. New HIV-1(JRCSF) variants efficiently use CCR5(HHMH), a chimera containing murine extracellular loop 2. The adapted virus induces large syncytia in cells containing either wild-type or mutant CCR5s and has multiple gp120 mutations that occurred independently in CCR5(Delta18)-adapted virus. Accordingly, these variants interchangeably use CCR5(HHMH) or CCR5(Delta18). Additional analyses strongly support a novel energetic model for allosteric proteins, implying that the adaptive mutations reduce quaternary constraints holding gp41, thus lowering the activation energy barrier for membrane fusion without affecting bonds to specific CCR5 sites. In accordance with this mechanism, highly adapted HIV-1s require only one associated CCR5(HHMH), whereas poorly adapted viruses require several. However, because they are allosteric ensembles, complexes with additional co-receptors fuse more rapidly and efficiently than minimal ones. Similarly, wild-type HIV-1(JRCSF) is highly adapted to wild-type CCR5 and minimally requires one. The adaptive mutations cause resistances to diverse entry inhibitors and cluster appropriately in the gp120 trimer interface overlying gp41. We conclude that membrane fusion complexes are allosteric machines with an ensemble of compositions, and that HIV-1 adapts to entry limitations by gp120 mutations that reduce its allosteric hold on gp41. These results provide an important foundation for understanding the mechanisms that control membrane fusion and HIV-1's facile adaptability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920626      PMCID: PMC2704606          DOI: 10.1016/j.jmb.2007.09.016

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  48 in total

Review 1.  Protein-lipid interplay in fusion and fission of biological membranes.

Authors:  Leonid V Chernomordik; Michael M Kozlov
Journal:  Annu Rev Biochem       Date:  2003       Impact factor: 23.643

2.  Evidence that rabies virus forms different kinds of fusion machines with different pH thresholds for fusion.

Authors:  Stéphane Roche; Yves Gaudin
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses.

Authors:  S E Kuhmann; E J Platt; S L Kozak; D Kabat
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1.

Authors:  Kevin Olivieri; Robert M Scoggins; Yeou-cherng Bor; Aprille Matthews; David Mark; James R Taylor; David Chernauskas; Marie-Louise Hammarskjöld; David Rekosh; David Camerini
Journal:  Virology       Date:  2006-09-26       Impact factor: 3.616

5.  Comparison of experimental binding data and theoretical models in proteins containing subunits.

Authors:  D E Koshland; G Némethy; D Filmer
Journal:  Biochemistry       Date:  1966-01       Impact factor: 3.162

6.  Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity.

Authors:  B Chesebro; K Wehrly
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor.

Authors:  E J Platt; N Madani; S L Kozak; D Kabat
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 9.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

Authors:  R Wyatt; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

10.  Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers.

Authors:  T Danieli; S L Pelletier; Y I Henis; J M White
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

View more
  19 in total

1.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

2.  Mechanisms of receptor/coreceptor-mediated entry of enveloped viruses.

Authors:  Sarah A Nowak; Tom Chou
Journal:  Biophys J       Date:  2009-04-08       Impact factor: 4.033

3.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

Review 4.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

5.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

7.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

8.  Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.

Authors:  Robert A Ogert; Lei Ba; Yan Hou; Catherine Buontempo; Ping Qiu; Jose Duca; Nicholas Murgolo; Peter Buontempo; Robert Ralston; John A Howe
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

9.  Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Authors:  Caroline Agrawal-Gamse; Fang-Hua Lee; Beth Haggarty; Andrea P O Jordan; Yanjie Yi; Benhur Lee; Ronald G Collman; James A Hoxie; Robert W Doms; Meg M Laakso
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

10.  Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections.

Authors:  Stanca M Ciupe
Journal:  J Math Biol       Date:  2014-09-05       Impact factor: 2.259

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.